EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

High chromosomal instability is associated with higher 10‐year risks of recurrence for hormone receptor‐positive, human epidermal growth factor receptor 2‐negative breast cancer patients: clinical evidence from a large‐scale, multiple‐site, retrospective study

Yu-Yang Liao, Jianfei Fu, Xiang Lu, Ziliang Qian, Yang Yu, Liang Zhu, Jia-Ni Pan, Pu-Chun Li, Qiao-Yan Zhu, Xiaolin Li, Wenyong Sun, Xiao-Jia Wang und 1 weitere

The Journal of Pathology: Clinical Research · 2024

DOI: 10.1002/2056-4538.70011 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Pathology: Clinical Research, 2024. Verfasst von Yu-Yang Liao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, PR China. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Neoplasm Recurrence, Local, Chromosomal Instability. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province, Key Project of the Zhejiang Provincial Health Major Science and Technology Plan, Key Research and Development Program of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long‐term survival varies among hormone receptor‐positive (HR+) and human epidermal growth factor receptor 2‐negative (HER2−) breast cancer patients and is seriously impaired by metastasis. Chromosomal instability (CIN) was one of the key drivers of breast cancer metastasis. Here we evaluate CIN and 10‐year invasive disease‐free survival (iDFS) and overall survival (OS) in HR+/HER2−– breast cancer. In this large‐scale, multiple‐site, retrospective study, 354 HR+/HER2− breast cancer patients were recruited. Of these, 204 patients were used for internal training, 70 for external validation, and 80 for cross‐validation. All medical records were carefully reviewed to obtain the disease recurrence information. Formalin‐fixed paraffin‐embedded tissue samples were collected, followed by low‐pass whole‐genome sequencing with a median genome coverage of 1.86X using minimal 1 ng DNA input. CIN was then assessed using a customized bioinformatics workflow. Three or more instances of CIN per sample was defined as high CIN and the frequency was 42.2% (86/204) in the internal cohort. High CIN correlated significantly with increased lymph node metastasis, vascular invasion, progesterone receptor negative status, HER2 low, worse pathological type, and performed as an independent prognostic factor for HR+/− breast cancer. Patients with high CIN had shorter iDFS and OS than those with low CIN [10‐year iDFS 11.1% versus 82.2%, hazard ratio (HR) = 11.12, p < 0.01; 10‐year OS 45.7% versus 94.3%, HR = 14.17, p < 0.01]. These findings were validated in two external cohorts with 70 breast cancer patients. Moreover, high CIN could predict the prognosis more accurately than Adjuvant! Online score (10‐year iDFS 11.1% versus 48.6%, HR = 2.71, p < 0.01). Cross‐validation analysis found that high consistency (83.8%) was observed between CIN and MammaPrint score, while only 45% between CIN and Adjuvant! Online score. In conclusion, high CIN is an independent prognostic indicator for HR+/HER2− breast cancer with shorter iDFS and OS and holds promise for predicting recurrence and metastasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesNeoplasm Recurrence, LocalChromosomal InstabilityHumansFemaleRetrospective StudiesMiddle AgedAdultAgedReceptors, ProgesteroneReceptors, EstrogenBiomarkers, TumorDisease-Free SurvivalRisk Factors

Stichwörter der Autor:innen

breast cancerchromosomal instabilityhormone receptor‐positiveprognosisrecurrence

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneReceptors, EstrogenBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Department of Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, PR China.
  • Postgraduate Training Base Alliance of Wenzhou Medical University, Zhejiang Cancer Hospital, Hangzhou, PR China.
  • Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine (Jinhua Municipal Central Hospital), Jinhua, PR China.
  • Department of Breast Disease, Affiliated Hospital of Jiaxing University (First Hospital of Jiaxing), Jiaxing, PR China.
  • Hongyuan Biotech, Biobay, Suzhou, PR China.
  • Department of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou, PR China.

ORCID-Profile: Wen-Ming Cao

Förderung

  • Natural Science Foundation of Zhejiang Province
  • Key Project of the Zhejiang Provincial Health Major Science and Technology Plan
  • Key Research and Development Program of Zhejiang Province

Zitieren

APA

Liao, Y. Y., Fu, J., Lu, X., Qian, Z., Yu, Y., Zhu, L., Pan, J. N., Li, P. C., Zhu, Q. Y., Li, X., Sun, W., Wang, X. J., & Cao, W. M. (2024). High chromosomal instability is associated with higher 10‐year risks of recurrence for hormone receptor‐positive, human epidermal growth factor receptor 2‐negative breast cancer patients: clinical evidence from a large‐scale, multiple‐site, retrospective study. The Journal of Pathology: Clinical Research. https://doi.org/10.1002/2056-4538.70011

Vancouver

Liao YY, Fu J, Lu X, Qian Z, Yu Y, Zhu L, et al. High chromosomal instability is associated with higher 10‐year risks of recurrence for hormone receptor‐positive, human epidermal growth factor receptor 2‐negative breast cancer patients: clinical evidence from a large‐scale, multiple‐site, retrospective study. The Journal of Pathology: Clinical Research. 2024. doi:10.1002/2056-4538.70011

BibTeX
@article{Liao2024,
  author = {Liao, Yu-Yang and Fu, Jianfei and Lu, Xiang and Qian, Ziliang and Yu, Yang and Zhu, Liang and Pan, Jia-Ni and Li, Pu-Chun and Zhu, Qiao-Yan and Li, Xiaolin and Sun, Wenyong and Wang, Xiao-Jia and Cao, Wen-Ming},
  title = {High chromosomal instability is associated with higher 10‐year risks of recurrence for hormone receptor‐positive, human epidermal growth factor receptor 2‐negative breast cancer patients: clinical evidence from a large‐scale, multiple‐site, retrospective study},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2024},
  doi = {10.1002/2056-4538.70011}
}
Kostenlos starten →